Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLT006
MIFTS: 46

Bilateral Breast Cancer

Categories: Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Bilateral Breast Cancer

About this section

MalaCards integrated aliases for Bilateral Breast Cancer:

Name: Bilateral Breast Cancer 12 54 15 71
Bilateral Breast Carcinoma 12 6

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:6741
NCIt 49 C8287
UMLS 71 C0281267
Sources

Summaries for Bilateral Breast Cancer

About this section
Disease Ontology : 12 A breast carcinoma that is characterized by an individual having breast cancer in both breasts, either simultaneously or at different times.

MalaCards based summary : Bilateral Breast Cancer, also known as bilateral breast carcinoma, is related to ataxia-telangiectasia and synchronous bilateral breast carcinoma. An important gene associated with Bilateral Breast Cancer is BRCA2 (BRCA2 DNA Repair Associated), and among its related pathways/superpathways are ERK Signaling and Gene Expression. The drugs Sargramostim and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include breast, ovary and lung, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Bilateral Breast Cancer

About this section

Diseases related to Bilateral Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 348)
# Related Disease Score Top Affiliating Genes
1 ataxia-telangiectasia 30.4 CHEK2 BRCA2 BRCA1 ATM
2 synchronous bilateral breast carcinoma 29.8 PGR BRCA2 BRCA1
3 papillary serous adenocarcinoma 29.6 PGR BRCA2 BRCA1
4 gynecomastia 29.5 PGR ESR1 ERBB2
5 thyroid carcinoma 29.5 PTEN PIK3CA CDH1
6 liposarcoma 29.5 PTEN PIK3CA CDKN2A
7 cervical adenocarcinoma 29.4 PTEN ESR1 ERBB2 CDKN2A
8 comedo carcinoma 29.2 PGR ESR1 ERBB2
9 estrogen excess 29.1 PTEN PGR ESR1
10 mammary paget's disease 29.1 PGR ESR1 ERBB2
11 gastrointestinal stromal tumor 29.1 PTEN ERBB2 CDKN2A CDH1
12 breast fibroadenoma 28.9 PGR ESR1 ERBB2 BRCA1
13 breast disease 28.8 PGR FHIT ESR1 ERBB2 BRCA2 BRCA1
14 leiomyosarcoma 28.8 PGR ESR1 CDKN2A
15 papillary carcinoma 28.7 PGR ESR1 ERBB2 CDH1
16 tubular adenocarcinoma 28.7 PGR ESR1 ERBB2 CDH1
17 lobular neoplasia 28.6 PGR ESR1 ERBB2 CDH1 BRCA2 BRCA1
18 female breast cancer 28.5 PGR PALB2 ESR1 ERBB2 BRCA2 BRCA1
19 carcinosarcoma 28.4 PTEN PIK3CA PGR ERBB2 CDH1
20 serous cystadenocarcinoma 28.4 PTEN PIK3CA PGR ERBB2 BRCA2 BRCA1
21 hereditary breast ovarian cancer syndrome 28.3 RAD51 PTEN PALB2 MLH1 CHEK2 CDKN2A
22 mucinous adenocarcinoma 28.2 PGR MLH1 ESR1 ERBB2 CDKN2A
23 squamous cell carcinoma 28.2 PTEN PIK3CA FHIT ERBB2 CHEK2 CDKN2A
24 adenocarcinoma 28.2 PTEN PIK3CA MLH1 ERBB2 CDKN2A CDH1
25 thyroid gland cancer 28.1 PTEN PIK3CA ESR1 ERBB2 CDKN2A CDH1
26 in situ carcinoma 28.0 PTEN PGR ESR1 ERBB2 CDKN2A CDH1
27 cowden syndrome 28.0 RAD51 PTEN PIK3CA PALB2 MLH1 ERBB2
28 li-fraumeni syndrome 27.9 PTEN PALB2 MLH1 ESR1 ERBB2 CHEK2
29 breast ductal carcinoma 27.9 PTEN PGR ESR1 ERBB2 CDH1 BRCA2
30 endometrial adenocarcinoma 27.4 PTEN PGR MLH1 ESR1 ERBB2 CDKN2A
31 ductal carcinoma in situ 27.4 PTEN PIK3CA PGR ESR1 ERBB2 CDKN2A
32 adenoid cystic carcinoma 27.1 PTEN PIK3CA PGR ERBB2 CHEK2 CDKN2A
33 cervical cancer 27.0 PTEN PIK3CA MLH1 FHIT ESR1 ERBB2
34 pancreatic cancer 26.7 RAD51 PTEN PIK3CA PALB2 MLH1 FHIT
35 breast cancer 26.5 RAD51 PTEN PIK3CA PGR PALB2 MLH1
36 endometrial cancer 26.1 RAD51 PTEN PIK3CA PGR MLH1 ESR1
37 gastric cancer 26.0 PTEN PIK3CA PGR MLH1 FHIT ESR1
38 prostate cancer 25.9 RAD51 PTEN PIK3CA PGR ESR1 ERBB2
39 sporadic breast cancer 25.9 RAD51 PTEN PGR PALB2 MLH1 FHIT
40 ovarian cancer 24.7 RAD51 PTEN PIK3CA PGR PALB2 NBR1
41 hereditary site-specific ovarian cancer syndrome 10.6 BRCA2 BRCA1
42 rare malignant breast tumor 10.6 BRCA2 BRCA1
43 tetraploidy 10.5 BRCA2 BRCA1
44 cancerophobia 10.5 BRCA2 BRCA1
45 nosophobia 10.5 BRCA2 BRCA1
46 scrotum squamous cell carcinoma 10.5 CHEK2 ATM
47 breast-ovarian cancer, familial 2 10.4 BRCA2 BRCA1
48 tracheoesophageal fistula with or without esophageal atresia 10.4 PALB2 BRCA2
49 familiar ovarian carcinoma 10.4 PIK3CA BRCA1
50 breast cystic hypersecretory carcinoma 10.3 ERBB2 CDH1

Graphical network of the top 20 diseases related to Bilateral Breast Cancer:



Diseases related to Bilateral Breast Cancer
Sources

Symptoms & Phenotypes for Bilateral Breast Cancer

About this section

GenomeRNAi Phenotypes related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

26 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.77 PIK3CA
2 Decreased viability GR00221-A-1 10.77 CDKN2A ESR1 PIK3CA
3 Decreased viability GR00221-A-2 10.77 BRCA1 CHEK2 ESR1 PIK3CA
4 Decreased viability GR00221-A-3 10.77 ATM BRCA1 CDKN2A CHEK2 ERBB2
5 Decreased viability GR00221-A-4 10.77 ATM CDKN2A CHEK2 ERBB2 ESR1 PIK3CA
6 Decreased viability GR00301-A 10.77 BRCA1
7 Decreased viability GR00342-S-2 10.77 CHEK2
8 Decreased viability GR00402-S-2 10.77 ATM BRCA1 CDKN2A CHEK2 ERBB2 ESR1
9 Decreased viability in esophageal squamous lineage GR00235-A 10.15 BRCA1 BRCA2 CDH1 CDKN2A CHEK2 ERBB2
10 Decreased homologous recombination repair frequency GR00151-A-1 10.06 BRCA1 RAD51
11 Decreased homologous recombination repair frequency GR00151-A-2 10.06 BRCA1 RAD51
12 Decreased homologous recombination repair frequency GR00236-A-3 10.06 BRCA1 BRCA2 PALB2 RAD51
13 Increased homologous recombination repair frequency GR00236-A-1 10 BRCA1 BRCA2 PALB2 PGR RAD51
14 Increased homologous recombination repair frequency GR00236-A-2 10 ATM BRCA1 BRCA2 PALB2 PGR RAD51
15 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.84 ATM BRCA1 BRCA2 CDKN2A CHEK2 MLH1
16 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.84 ATM BRCA1 BRCA2 CDKN2A CHEK2 MLH1
17 Apoptosis resistance GR00093-A-0 9.78 ATM CDKN2A CHEK2 PTEN
18 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.7 ATM BRCA1 BRCA2 CHEK2 MLH1 PALB2
19 Decreased viability after ionizing radiation GR00232-A-2 9.58 ATM BRCA1 BRCA2
20 Decreased viability with cisplatin GR00101-A-4 9.5 BRCA1 BRCA2 RAD51
21 Synthetic lethal with cisplatin GR00101-A-1 9.13 BRCA1 BRCA2 RAD51

MGI Mouse Phenotypes related to Bilateral Breast Cancer:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.43 ATM BRCA1 BRCA2 CDH1 CDKN2A CHEK2
2 homeostasis/metabolism MP:0005376 10.32 ATM BRCA1 BRCA2 CDH1 CDKN2A CHEK2
3 embryo MP:0005380 10.31 ATM BRCA1 BRCA2 CDH1 CDKN2A ERBB2
4 endocrine/exocrine gland MP:0005379 10.3 ATM BRCA1 BRCA2 CDH1 CDKN2A CHEK2
5 cardiovascular system MP:0005385 10.27 ATM BRCA1 CDH1 CDKN2A ERBB2 ESR1
6 hematopoietic system MP:0005397 10.27 ATM BRCA1 BRCA2 CDKN2A CHEK2 ESR1
7 immune system MP:0005387 10.27 ATM BRCA1 BRCA2 CDH1 CDKN2A CHEK2
8 growth/size/body region MP:0005378 10.25 ATM BRCA1 BRCA2 CDH1 CDKN2A ERBB2
9 integument MP:0010771 10.25 ATM BRCA1 BRCA2 CDH1 CDKN2A ERBB2
10 mortality/aging MP:0010768 10.24 ATM BRCA1 BRCA2 CDH1 CDKN2A CHEK2
11 digestive/alimentary MP:0005381 10.2 BRCA1 BRCA2 CDH1 CDKN2A ERBB2 ESR1
12 neoplasm MP:0002006 10.1 ATM BRCA1 BRCA2 CDH1 CDKN2A CHEK2
13 limbs/digits/tail MP:0005371 10.01 BRCA1 BRCA2 ERBB2 ESR1 NBR1 PALB2
14 muscle MP:0005369 9.87 BRCA1 CDKN2A ERBB2 ESR1 PGR PIK3CA
15 nervous system MP:0003631 9.85 ATM BRCA1 BRCA2 CDKN2A CHEK2 ERBB2
16 reproductive system MP:0005389 9.73 ATM BRCA1 BRCA2 CDH1 CDKN2A CHEK2
17 skeleton MP:0005390 9.28 BRCA1 BRCA2 CDKN2A ERBB2 ESR1 NBR1
Sources

Drugs & Therapeutics for Bilateral Breast Cancer

About this section

Drugs for Bilateral Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
2
leucovorin Approved Phase 2 58-05-9 6006 143
3
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
4
Sulindac Approved, Investigational Phase 2 38194-50-2 5352 1548887
5
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
6
Emodepside Investigational, Vet_approved Phase 2 155030-63-0
7 Vaccines Phase 2
8 Vitamins Phase 2
9 Trace Elements Phase 2
10 Vitamin B Complex Phase 2
11 Alkylating Agents Phase 2
12 Micronutrients Phase 2
13 Vitamin B9 Phase 2
14 Nutrients Phase 2
15 Hematinics Phase 2
16 Immunosuppressive Agents Phase 2
17 Folate Phase 2
18 Immunologic Factors Phase 2
19 Epothilone B Phase 2
20 Epothilones Phase 2
21 Antimitotic Agents Phase 2
22 Estrogens Phase 2
23 Hormone Antagonists Phase 2
24 Hormones Phase 2
25 Antirheumatic Agents Phase 2
26 Anti-Inflammatory Agents Phase 2
27 Aromatase Inhibitors Phase 2
28 Anti-Inflammatory Agents, Non-Steroidal Phase 2
29 Cyclooxygenase Inhibitors Phase 2
30 Analgesics, Non-Narcotic Phase 2
31 Estrogen Antagonists Phase 2
32 Steroid Synthesis Inhibitors Phase 2
33 Estrogen Receptor Antagonists Phase 2
34 Analgesics Phase 2
35
Progesterone Approved, Vet_approved Phase 1 57-83-0 5994
36 Progestins Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer Recruiting NCT03012100 Phase 2 Cyclophosphamide
2 A Phase II Randomized Study of Ixabepilone vs. Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2/Neu-Negative Breast Cancer Active, not recruiting NCT00877500 Phase 2 Ixabepilone
3 NSAID Effects on Clinical and Imaging Breast Biomarkers Active, not recruiting NCT01761877 Phase 2 Sulindac
4 A Phase 1b Study of M6620 in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer Not yet recruiting NCT04052555 Phase 1 ATR Kinase Inhibitor M6620
5 Genetic Counseling for Breast Cancer Survivors (GC for BC) Completed NCT02451735
6 Longitudinal Observational Study About the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer Completed NCT03669952
7 Dept. of Radiation Oncology, PGIMER, Chandigarh Completed NCT04175821
8 Establishment of Normal High Risk Breast Epithelial Cell Cultures, and A High Risk Cell Line and Tissue Repository From Breast Tissue From Women at High Risk of Breast Cancer Completed NCT00032201
9 Genome-Wide Association Study of Radiation Exposure and Bilateral Breast Cancer Active, not recruiting NCT00903591

Search NIH Clinical Center for Bilateral Breast Cancer

Sources

Genetic Tests for Bilateral Breast Cancer

About this section
Sources

Anatomical Context for Bilateral Breast Cancer

About this section

MalaCards organs/tissues related to Bilateral Breast Cancer:

40
Breast, Ovary, Lung, Thyroid, Lymph Node, Skin, Testes
Sources

Publications for Bilateral Breast Cancer

About this section

Articles related to Bilateral Breast Cancer:

(show top 50) (show all 830)
# Title Authors PMID Year
1
A novel de novo BRCA2 mutation of paternal origin identified in a Spanish woman with early onset bilateral breast cancer. 54 61
19649703 2010
2
A novel BRCA2 mutation that segregates with breast and prostate cancer in a Spanish family. 54 61
19288190 2010
3
Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. 54 61
20104584 2010
4
Robotic resection of intraductal neoplasm of the pancreas. 54 61
19698031 2009
5
A novel deletion of BRCA1 gene that eliminates the ATG initiation codon without affecting the promoter region. 54 61
19393826 2009
6
Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer. 54 61
19372713 2009
7
Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. 54 61
19153073 2009
8
Accuracy of the BRCAPRO model among women with bilateral breast cancer. 54 61
19127556 2009
9
Identification of a de novo BRCA1 mutation in a woman with early onset bilateral breast cancer. 54 61
19629752 2009
10
Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer. 54 61
18264724 2008
11
Altered DNA binding by the human Rad51-R150Q mutant found in breast cancer patients. 54 61
17666788 2007
12
[Analysis of the mutation of BRCA1 gene in 70 Uigur women breast cancer patients in Xinjiang]. 54 61
17557253 2007
13
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. 54 61
16331614 2006
14
Association of common ATM polymorphism with bilateral breast cancer. 54 61
15756685 2005
15
A comparison of bilateral breast cancers in BRCA carriers. 54 61
15941968 2005
16
BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients. 54 61
15319244 2004
17
ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer. 54 61
14562025 2003
18
Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. 54 61
12673797 2003
19
Sex hormone-binding globulin polymorphisms in familial and sporadic breast cancer. 54 61
12151349 2002
20
BRCA1 and BRCA2 mutations in Russian familial breast cancer. 54 61
11793480 2002
21
Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing. 54 61
11802208 2002
22
Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer. 54 61
11556836 2001
23
BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age. 54 61
11389159 2001
24
Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families. 54 61
11149425 2001
25
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. 54 61
11130383 2000
26
Frequency of germ-line BRCA1 mutations among Spanish families from a Mediterranean area. 54 61
10737987 2000
27
Detection of BRCA1 and BRCA2 mutations in breast cancer families by a comprehensive two-stage screening procedure. 54 61
10699917 2000
28
Identification of Rad51 alteration in patients with bilateral breast cancer. 54 61
10807537 2000
29
BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer. 54 61
10573018 1999
30
Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. 54 61
10188893 1999
31
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. 54 61
9333265 1997
32
Abnormal FHIT transcripts in human breast carcinomas: a clinicopathological and epidemiological analysis of 61 Japanese cases. 54 61
9157994 1997
33
BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. 54 61
9145677 1997
34
Germline mutation of BRCA1 in Japanese breast cancer families. 54 61
7627958 1995
35
Estrogen and progesterone receptor content in bilateral breast cancer. 54 61
7651928 1995
36
Genetic analysis of the BRCA1 region in a large breast/ovarian family: refinement of the minimal region containing BRCA1. 54 61
8281142 1993
37
Bilateral breast cancer: one disease or two? 54 61
1663803 1991
38
Carcinoma erysipeloides as the presenting feature for bilateral breast carcinoma. 61
32031679 2020
39
Detection of Germline Mutations in Breast Cancer Patients with Clinical Features of Hereditary Cancer Syndrome Using a Multi-Gene Panel Test. 61
32019277 2020
40
Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors. 61
31926487 2020
41
The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer. 61
31933123 2020
42
Endometrial Endometrioid Carcinoma With Ovarian Metastasis Showing Morula-like Features in a Patient With Cowden Syndrome: A Case Report. 61
30676432 2020
43
Systemic investigations into the molecular features of bilateral breast cancer for diagnostic purposes. 61
31835926 2020
44
Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer. 61
31119730 2020
45
Surgery for Killian-Jamieson diverticulum: a report of two cases. 61
31933008 2020
46
A Nanoscale Metal-Organic Framework to Mediate Photodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Enhance Antigen Presentation and Cancer Immunotherapy. 61
31642163 2020
47
Skin-sparing Mastectomy and Immediate Nipple Graft for Large, Ptotic Breast. 61
31897337 2019
48
Worse characteristics can predict survival effectively in bilateral primary breast cancer: A competing risk nomogram using the SEER database. 61
31663683 2019
49
Redefining Eligibility by Analyzing Canceled Intraoperative Radiotherapy as a Boost for Patients Undergoing Breast-Conserving Treatment. 61
31520209 2019
50
The yield of full BRCA1/2 genotyping in Israeli Arab high-risk breast/ovarian cancer patients. 61
31368036 2019
Sources

Variations for Bilateral Breast Cancer

About this section

ClinVar genetic disease variations for Bilateral Breast Cancer:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ATM NM_000051.3(ATM):c.2021A>G (p.His674Arg)SNV Conflicting interpretations of pathogenicity 141183 rs201762714 11:108124663-108124663 11:108253936-108253936
Sources

Expression for Bilateral Breast Cancer

About this section
Search GEO for disease gene expression data for Bilateral Breast Cancer.
Sources

Pathways for Bilateral Breast Cancer

About this section

Pathways related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.78 RAD51 PTEN ESR1 ERBB2 CHEK2 CDKN2A
2
Gene Expression 65
Show member pathways
 13.76 PTEN PGR MLH1 ESR1 ERBB2 CHEK2
3
Cell Cycle, Mitotic 65
Show member pathways
 13.39 RAD51 MLH1 CHEK2 CDKN2A BRCA2 BRCA1
4
DNA Double-Strand Break Repair 65
Show member pathways
 13.18 RAD51 PALB2 MLH1 CHEK2 BRCA2 BRCA1
5
Regulation of TP53 Activity 65
Show member pathways
 12.94 PTEN MLH1 CHEK2 CDKN2A BRCA1 ATM
6
TCR Signaling (Qiagen) 63
Show member pathways
 12.9 RAD51 MLH1 CHEK2 BRCA2 BRCA1 ATM
7
Endometrial cancer 36
Show member pathways
 12.78 RAD51 PTEN PIK3CA MLH1 ERBB2 CDKN2A
8
Pathways in cancer 36
12.75 RAD51 PTEN PIK3CA MLH1 ESR1 ERBB2
9
Development HGF signaling pathway 22
Show member pathways
 12.69 PTEN PIK3CA ESR1 ERBB2 CDH1
10
Chks in Checkpoint Regulation 63
Show member pathways
 12.68 RAD51 ESR1 CHEK2 BRCA2 BRCA1 ATM
11
Gastric cancer 36
Show member pathways
 12.52 PTEN PIK3CA PGR MLH1 ESR1 ERBB2
12
MicroRNAs in cancer 36
12.5 PTEN PIK3CA ERBB2 CDKN2A BRCA1 ATM
13
Meiosis 65
Show member pathways
 12.48 RAD51 MLH1 BRCA2 BRCA1 ATM
14
Prolactin Signaling Pathway 1 36
Show member pathways
 12.44 PTEN PIK3CA ESR1 ERBB2
15
DNA Damage 4
12.42 RAD51 MLH1 CHEK2 CDKN2A BRCA2 BRCA1
16
Apoptosis Pathway 70
Show member pathways
 12.41 PIK3CA ERBB2 CHEK2 ATM
17
DNA Damage Response 1
Show member pathways
 12.34 RAD51 PTEN CHEK2 CDKN2A BRCA1 ATM
18
Cell cycle 1 36
12.33 CHEK2 CDKN2A CDH1 ATM
19
Human T-cell leukemia virus 1 infection 36
12.32 PTEN PIK3CA CHEK2 CDKN2A ATM
20
Homologous DNA Pairing and Strand Exchange 65
Show member pathways
 12.27 RAD51 PALB2 BRCA2 BRCA1 ATM
21
p53 Signaling 63
Show member pathways
 12.23 PTEN CHEK2 BRCA1 ATM
22
Cell cycle Role of SCF complex in cell cycle regulation 22
Show member pathways
 12.21 PGR ESR1 CHEK2 CDKN2A BRCA1
23
Cellular senescence (KEGG) 36
12.16 PTEN PIK3CA CHEK2 CDKN2A ATM
24
Resolution of D-loop Structures through Holliday Junction Intermediates 65
Show member pathways
 12.12 RAD51 PALB2 BRCA2 BRCA1 ATM
25
DNA Damage Response (only ATM dependent) 1
11.97 PTEN PIK3CA ERBB2 CDKN2A ATM
26
Signaling by ERBB4 65
Show member pathways
 11.94 PIK3CA PGR ESR1 ERBB2
27
Glioma 36
Show member pathways
 11.92 PTEN PIK3CA FHIT ESR1 ERBB2 CDKN2A
28
ATM Pathway 63
Show member pathways
 11.84 RAD51 CHEK2 BRCA1 ATM
29
Fanconi anemia pathway 36 65
11.84 RAD51 PALB2 MLH1 BRCA2 BRCA1
30
Small cell lung cancer 36
11.83 PTEN PIK3CA FHIT
31
BRCA1 Pathway 63
Show member pathways
 11.77 RAD51 CHEK2 BRCA2 BRCA1 ATM
32
Integrated Breast Cancer Pathway 1
11.75 RAD51 PTEN ESR1 CHEK2 CDH1 BRCA2
33
Regulation of TP53 Expression and Degradation 65
Show member pathways
 11.72 CHEK2 CDKN2A ATM
34
Bladder cancer 36 1
11.71 ERBB2 CDKN2A CDH1
35
Central carbon metabolism in cancer 36
11.68 PTEN PIK3CA ERBB2
36
Platinum drug resistance 36
11.66 PIK3CA MLH1 ERBB2 CDKN2A BRCA1 ATM
37
Pathways Affected in Adenoid Cystic Carcinoma 1
11.55 PTEN PIK3CA ERBB2 CHEK2 BRCA1 ATM
38
Integrated Cancer Pathway 1
11.49 PTEN CHEK2 BRCA1 ATM
39
DNA damage_ATM/ATR regulation of G1/S checkpoint 22
11.47 CHEK2 BRCA1 ATM
40
FOXM1 transcription factor network 1
11.38 ESR1 CHEK2 BRCA2
41
Ovarian Infertility Genes 1
11.31 PGR MLH1 ATM
42
a6b1 and a6b4 Integrin signaling 1
11.29 PIK3CA ERBB2 CDH1
43
BARD1 signaling events 1
11.25 RAD51 BRCA1 ATM
Sources

GO Terms for Bilateral Breast Cancer

About this section

Cellular components related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.18 RAD51 PTEN PGR PALB2 MLH1 FHIT
2 cytoplasm GO:0005737 10.1 RAD51 PTEN PIK3CA PGR NBR1 FHIT
3 nucleoplasm GO:0005654 9.73 RAD51 PTEN PGR PALB2 NBR1 MLH1
4 PML body GO:0016605 9.58 RAD51 PTEN CHEK2
5 condensed nuclear chromosome GO:0000794 9.5 RAD51 MLH1 BRCA1
6 condensed chromosome GO:0000793 9.33 RAD51 MLH1 BRCA1
7 lateral element GO:0000800 8.8 RAD51 BRCA2 BRCA1

Biological processes related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 10.01 PTEN FHIT CHEK2 CDKN2A BRCA1 ATM
2 cell cycle GO:0007049 9.99 MLH1 CHEK2 CDKN2A BRCA2 BRCA1 ATM
3 positive regulation of gene expression GO:0010628 9.97 PTEN ERBB2 CDKN2A BRCA1 ATM
4 positive regulation of transcription, DNA-templated GO:0045893 9.97 ESR1 CHEK2 CDKN2A CDH1 BRCA2 BRCA1
5 cellular response to DNA damage stimulus GO:0006974 9.8 RAD51 PALB2 MLH1 CHEK2 BRCA2 BRCA1
6 double-strand break repair GO:0006302 9.77 CHEK2 BRCA2 BRCA1
7 double-strand break repair via nonhomologous end joining GO:0006303 9.76 MLH1 BRCA1 ATM
8 DNA recombination GO:0006310 9.71 RAD51 PALB2 BRCA2 BRCA1
9 DNA repair GO:0006281 9.7 RAD51 PALB2 MLH1 CHEK2 BRCA2 BRCA1
10 cellular response to gamma radiation GO:0071480 9.65 RAD51 CHEK2 ATM
11 DNA double-strand break processing GO:0000729 9.63 BRCA1 ATM
12 reciprocal meiotic recombination GO:0007131 9.63 RAD51 MLH1 ATM
13 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.62 PIK3CA ATM
14 inner cell mass cell proliferation GO:0001833 9.62 PALB2 BRCA2
15 meiotic telomere clustering GO:0045141 9.61 MLH1 ATM
16 telomere maintenance via recombination GO:0000722 9.61 RAD51 BRCA2
17 DNA damage induced protein phosphorylation GO:0006975 9.6 CHEK2 ATM
18 chromosome organization involved in meiotic cell cycle GO:0070192 9.58 RAD51 ATM
19 cellular response to indole-3-methanol GO:0071681 9.56 CDH1 BRCA1
20 negative regulation of immature T cell proliferation in thymus GO:0033088 9.55 ERBB2 CDKN2A
21 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.54 CHEK2 BRCA2 BRCA1
22 chordate embryonic development GO:0043009 9.52 BRCA2 BRCA1
23 replicative senescence GO:0090399 9.5 CHEK2 CDKN2A ATM
24 mitotic recombination-dependent replication fork processing GO:1990426 9.43 RAD51 BRCA2
25 double-strand break repair via homologous recombination GO:0000724 9.35 RAD51 PALB2 BRCA2 BRCA1 ATM
26 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.02 MLH1 CHEK2 BRCA2 BRCA1 ATM

Molecular functions related to Bilateral Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.16 RAD51 PTEN PIK3CA PGR PALB2 NBR1
2 DNA binding GO:0003677 9.97 RAD51 PGR PALB2 ESR1 CDKN2A BRCA2
3 single-stranded DNA binding GO:0003697 9.58 RAD51 MLH1 BRCA2
4 nucleotide binding GO:0000166 9.55 RAD51 FHIT ERBB2 CHEK2 ATM
5 enzyme binding GO:0019899 9.43 RAD51 PTEN PGR MLH1 ESR1 BRCA1
6 1-phosphatidylinositol-3-kinase activity GO:0016303 9.32 PIK3CA ATM
7 identical protein binding GO:0042802 9.32 RAD51 PTEN PGR FHIT ESR1 ERBB2
Sources

Sources for Bilateral Breast Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....